EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy

NCT06194825 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Transthyretin Amyloid Cardiomyopathy

Interventions

DRUG: Eplontersen
DRUG: Placebo

Sponsor

AstraZeneca